Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

102 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-11-26

Study Completion Date

2024-11-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Phase II open-label, single-arm, multicenter, international study to evaluate the clinical activity of durvalumab in patients with Stage III unresectable NSCLC who are deemed to be ineligible for chemotherapy per Investigator assessment. Patients will be enrolled into 2 cohorts according to radiotherapy pretreatment dose (Cohort A: standard radiation therapy \[60 gray (Gy) ± 10% or hypofractionated bioequivalent dose (BED)\]; Cohort B: palliative radiation therapy \[40 to \< 54 Gy or hypofractionated BED\])

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

NCT03693300

Non-small Cell Lung Cancer (NSCLC)

COMPLETED PHASE2

Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.

NCT04642469

Carcinoma, Non- Small Cell Lung

COMPLETED PHASE3

A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients

NCT03706690

Carcinoma, Non-Small-Cell Lung

ACTIVE_NOT_RECRUITING PHASE3

Intensified Chemo-immuno-radiotherapy With Durvalumab for Stage III Non-Small Cell Lung Cancers

NCT04230408

Lung Neoplasms

COMPLETED PHASE2

First Real-world Data on Unresectable Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy

NCT03798535

NSCLC

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a Phase II open-label, single-arm, multicenter, international study to evaluate the clinical activity of durvalumab in patients with Stage III unresectable NSCLC who have an Eastern Cooperative Oncology Group (ECOG) PS of 0 to 2 and who were treated with radiotherapy but are ineligible for chemotherapy. Patients will be enrolled into 2 cohorts according to the dose of radiotherapy received prior to study entry (Cohort A: Standard Radiotherapy \[60 Gy ± 10% or hypofractionated BED\]; Cohort B: Palliative Radiotherapy \[40 to \< 54 Gy or hypofractionated BED\]). Patients must not have progressed following radiation therapy, and radiation therapy must be completed within 6 weeks (42 days) prior to first study drug administration. The last dose of radiation therapy is defined as the day of the last radiation treatment session. All patients will receive 1500 mg durvalumab via IV infusion every 4 weeks (q4w) for up to a maximum of 12 months (up to 13 doses/cycles)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-small Cell Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort A

Patients received standard radiotherapy \[60 gray (Gy) ± 10% or hypofractionated BED\] prior to study entry.

Group Type EXPERIMENTAL

Durvalumab

Intervention Type DRUG

All patients will receive 1500 mg durvalumab via IV infusion q4w for up to a maximum of 12 months.

Cohort B

Patients received palliative radiotherapy \[40 to \< 54 Gy or hypofractionated BED\] prior to study entry.

Group Type EXPERIMENTAL

Durvalumab

Intervention Type DRUG

All patients will receive 1500 mg durvalumab via IV infusion q4w for up to a maximum of 12 months.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Durvalumab

All patients will receive 1500 mg durvalumab via IV infusion q4w for up to a maximum of 12 months.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

MEDI4736

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Capable of giving signed informed consent.
2. Age ≥ 18 years at study entry.
3. Histologically or cytologically documented NSCLC with locally-advanced, unresectable Stage III disease.
4. Deemed ineligible for chemotherapy per Investigator assessment.
5. Receipt of radiation therapy that was completed within 42 days prior to first study drug administration.
6. Must have received a total dose of radiation of 40 to 66 Gy (standard or hypofractionated BED).
7. Must not have progressed following radiation therapy, as per Investigator assessed RECIST 1.1 criteria: a) Patients with measurable disease and/or nonmeasurable and/or no evidence of disease assessed at baseline by computed tomography /magnetic resonance imaging will be eligible for this study. b) Prior irradiated lesions may be considered measurable and selected as target lesions (TLs) providing they fulfill the other criteria for measurability.
8. World Health Organization/ECOG performance status of ≤2.
9. No prior exposure to immune-mediated therapy including, but not limited to, anti-CTLA-4, anti-PD-1, anti-PD-L1, and antiprogrammed cell death ligand 2 (anti-PD-L2) antibodies, excluding therapeutic anticancer vaccines.
10. Patients must have adequate organ and marrow function as defined below:

* Hemoglobin ≥ 9.0 g/dL
* Absolute neutrophil count ≥ 1.0 × 109 /L
* Platelet count ≥ 75 × 109/L
* Serum bilirubin ≤ 1.5 × the upper limit of normal (ULN). This will not apply to patients with confirmed Gilbert's syndrome.
* Alanine aminotransferase and aspartate aminotransferase ≤ 2.5 × ULN
* Measured creatinine clearance \> 30 mL/min or calculated CL \> 30 mL/min as determined by Cockcroft-Gault
11. Life expectancy of greater than 12 weeks.
12. Body weight greater than 30 kg at study entry and at first study drug administration

11. Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.
12. Receipt of live attenuated vaccine within 30 days prior to the first dose of durvalumab
13. Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of durvalumab.
14. Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab.
15. Participation in another clinical study with an IP administered in the last 4 weeks.
16. Concurrent enrollment in another clinical study, unless it is an observational (noninterventional) clinical study or during the follow-up period of an interventional study
17. Prior randomization or treatment in a previous durvalumab clinical study regardless of treatment arm assignment
18. Patients who refuse chemotherapy by their own decision.
19. Involvement in the planning and/or conduct of the study
20. Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control.
21. Judgment by the Investigator that the patient should not participate in the study
22. Genetics research study (optional):

Exclusion Criteria

1. Patients with locally-advanced NSCLC whose disease has progressed following radiation therapy.
2. Mixed small cell lung cancer and NSCLC histology.
3. History of allogeneic organ transplantation.
4. Active or prior documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative, systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome).
5. Uncontrolled intercurrent illness (e.g., ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris)
6. History of another primary malignancy except for (a) malignancy treated with curative intent and with no known active disease ≥ 5 years before the first study drug administration, (b) adequately treated nonmelanoma skin cancer or lentigo maligna without evidence of disease, and c) treated carcinoma in situ without evidence of disease.
7. History of leptomeningeal carcinomatosis
8. History of active primary immunodeficiency
9. Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus

Minimum Eligible Age

18 Years

Maximum Eligible Age

130 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No